Enzymatic characterization shows DDE restores antioxidant capacity and gut microbiota balance in C57BL/6J mice, highlighting its potential for detoxification.
Deoxynivalenol (DON), a mycotoxin produced by Fusarium species, severely contaminates grains and feed, posing a continuous threat to human and livestock health. In this study, the DON-degrading enzyme (DDE) gene from Devosia sp. JA3 was heterologously expressed in Escherichia coli. Enzyme kinetics revealed that DDE exhibited optimal activity at 37 °C and pH 7.0, with a Km of 0.32 mM and a Vmax of 563.3 nmol/(min·mg). Under optimized conditions, DDE efficiently oxidized DON to 3-keto-DON, achieving a degradation rate of 82.51% within 12 h. Further investigation in C57BL/6J mice showed that oral administration of 2 mg/kg DON significantly reduced antioxidant capacity, caused liver damage, impaired intestinal barrier function, induced intestinal inflammation and apoptosis, and disrupted the gut microbiota. DDE treatment effectively alleviated these DON-induced effects by restoring antioxidant capacity, ameliorating liver injury, downregulating pro-inflammatory and apoptotic genes, upregulating barrier-related genes, and restoring the gut microbiota balance, thereby protecting intestinal health. These findings demonstrate DDE’s excellent DON-degrading capacity and biosafety, providing new technical evidence for DON detoxification applications.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: